UroGen Pharma announces patient-reported outcomes on UGN-102

UroGen Pharma (URGN) announced patient-reported outcomes following treatment of patients with low-grade intermediate-risk non-muscle invasive bladder cancer, LG-IR-NMIBC, that showed investigational drug UGN-102 for intravesical solution achieved robust and durable complete response rates without negatively impacting quality of life. The data were presented at the AUA 2025 Annual Meeting in Las Vegas, Nevada. In the OPTIMA II, ATLAS, and ENVISION late-phase studies, most patients completed the questionnaires at baseline, three months, and 12 months or study end. Baseline scores indicated high levels of functioning and low symptom burden prior to treatment. UGN-102 did not cause sustained declines in functioning or symptom burden, and no measured domains or items exceeded the threshold for clinically significant worsening at three or 12 months, suggesting no negative impact on quality of life.